首頁 > 市場調查報告書 > 製藥

生物製劑基因治療學和RNAi

全球病毒載體生產市場：市場預測、類型（痘病毒、鉅細胞病毒、單純皰疹病毒載體、腺病毒載體）、用途（基因治療、疫苗）、區域分析（~2028）

市場調查報告書

商品編碼

1064123

全球病毒載體生產市場：市場預測、類型（痘病毒、鉅細胞病毒、單純皰疹病毒載體、腺病毒載體）、用途（基因治療、疫苗）、區域分析（~2028）

Viral Vector Manufacturing Market Forecasts to 2028 - Global Analysis By Type (Pox Virus, Cytomegalovirus, Herpes Simplex Virus Vectors, Adenoviral Vectors), Application (Gene Therapy, Vaccinology) and By Geography

出版日期: 2022年07月01日 | 出版商:

Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

預計全球病毒載體製造市場在預測期內將以 18.0% 的複合年增長率增長，到 2021 年達到 5.6651 億美元，到 2028 年達到 18.45 億美元。

本報告調查了全球病毒載體製造市場，並提供了全面的信息，包括市場概況、市場規模和預測、趨勢、增長和抑制因素，以及按類型/用途/地區進行的分析。

北美
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 義大利
- 法國
- 西班牙
- 其他歐洲
亞太地區
- 日本
- 中國
- 印度
- 澳大利亞
- 紐西蘭
- 韓國
- 其他亞太地區
南美洲
- 阿根廷
- 巴西
- 智利
- 其他南美洲
中東/非洲
- 沙特阿拉伯
- 阿拉伯聯合酋長國
- 卡塔爾
- 南非
- 其他中東/非洲

第 10 章主要發展

合同、夥伴關係、合作、合資企業
收購兼併
推出新產品
擴展
其他重要策略

第 11 章公司簡介

Merck KGaA
Thermo Fisher Scientific Inc.
Brammer Bio
Spark Therapeutics
Fujifilm Holdings Corporation
Lonza
Kaneka Eurogentec
Finvector Vision Therapies
Cobra Biologics
Uniqure
Oxford Biomedica
Massbiologics
Novasep
Regenxbio
Shape Therapeutics

簡介目錄圖表

Product Code: SMRC21698

According to Stratistics MRC, the Global Viral Vector Manufacturing Market is accounted for $668.48 million in 2022 and is expected to reach $1,804.59 million by 2028 growing at a CAGR of 18.0% during the forecast period. Viral vectors are manufactured for delivering genetic materials into the target cells in various genetic, vaccinology, and molecular biology applications. Also, viral vectors are exploited for discovering various therapeutic areas. Viral vectors are manufactured using viruses and animal or insect cell cultures.

There were over 9.5 thousand active drugs of chemical, synthetic origin, thus making it the top origin for pipeline drugs in terms of number of active drugs. The past five years have seen viral-vector-based gene therapies become a reality. To date, eight therapies have been approved by the US Food and Drug Administration (FDA) across three different types of viral vectors: adeno-associated virus (AAV), lentivirus, and herpes simplex virus. With 25 viral-vector therapeutics in late-stage development and another 120 in Phase II trials as of February 2022, the number of approved therapies is only expected to grow.

Market Dynamics:

Driver:

Increasing prevalence of infectious diseases

The growing worldwide burden of cancer, infectious diseases, and genetic disorders is increasing in several countries and therefore acting as the biggest driver of the market. Factors driving market growth include the increasing prevalence of genetic diseases, cancer, and infectious diseases, the increasing number of clinical trials of viral vectors, and the availability of funding for gene therapy development. The Viral Vector Manufacturing Market is growing significantly due to a rise in the number of gene therapy-based products in the market.

Restraint:

Short life of viral vectors

Viral vectors come with the disadvantage of having a short life. This is expected to have a negative impact on the growth of the market. Moreover, the high cost of gene-based medical therapies might hamper the demand for viral vectors during the forecast period.

Opportunity:

Emergence of molecular biology

The emergence of molecular biology is accelerating genomic sequencing that is further expected to reinforce precision medicine. The progress showcased by molecular biology and medical science are aligning gene therapy to a progressive borderline, thereby fostering the growth of the viral vector manufacturing for revolutionizing patient care. Moreover, with their increasing use in gene therapy for the treatment of several diseases such as cancer, metabolic diseases, and others, the demand for viral vector manufacturing is projected to rise.

Threat:

Highly regulated processes

Tedious and highly regulated processes for vector production and inadequate capacity for vector production are some of the key challenges in the market for viral vectors and plasmid DNA manufacturing. To overcome these challenges, more focused attempts are required.

The vaccinology segment is expected to be the largest during the forecast period

High employment of viral vectors in vaccine development owing to their efficiency-related advantages is the main factor driving the vaccinology sector. Some advantages are the potential to elicit a wide immune response, safety profiles, and easy manufacturing. The recent outbreak of the COVID-19 virus has driven the use of viral vectors in vaccine development. Although viral vectors were widely used for vaccine development before the emergence of COVID-19, the urgency to develop a vaccine against this virus has led the scientific community to repurpose the existing approaches. Non-replicating viral vectors are being used in the COVID-19 viral vector vaccines. Various companies have launched platforms for the clinical trial base manufacturing for addressing the bottlenecks associated with the viral vector supply chain amidst the pandemic situation. Such initiatives are attributive to drive manufacturing and research practices in viral vector academic organizations and CROs .

The research institutes segment is expected to have the highest CAGR during the forecast period

The increasing involvement of the research community in gene and cell therapy research activities is expected to increase the demand for viral vectors in the global market. An increase in the introduction of advanced therapies along with the rising number of gene therapy-based R&D programs by companies, pharmaceutical, and biopharmaceutical companies are emerging as the significant end-users of the market for viral vectors and plasmid DNA manufacturing. For instance, Abeona Therapeutics is one of such companies that is actively evaluating AAV9-based gene therapies for CLN1 and CLN3 diseases.

Region with largest share:

North America is projected to hold the largest market share owing to the high adoption rate of new therapies and the high incidence rate of cancer. The increasing prevalence of genetic and other chronic disorders, an aging population, growing demand for targeted and personalized medicine, and favorable government initiatives are the factors responsible for future market growth in the region. Many companies have been expanding their facilities and investing a significant amount of capital in the region. Educational and academic institutes have also been at the forefront of R&D investment. For instance, Harvard University announced that it was collaborating with contract development and manufacturing organizations (CDMOs) to develop a USD 50 million cell and viral vector manufacturing facility. Such initiatives are expected to boost the market growth in North America.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR due to the increasing research activities for the introduction of novel gene therapies in the untapped markets of this region. The strategies adopted by the key market players in Japan and the government initiatives promoting clinical trials in India are the key factors driving growth in the Asia Pacific viral vector manufacturing market. The viral vector manufacturing market is also driven by the government approvals to conduct trials related to the Ebola virus disease vaccine. An increasing number of clinical trials related to viral vector vaccine in China also drives the growth of the viral vector manufacturing market in this country.

Key players in the market

Some of the key players profiled in the Viral Vector Manufacturing Market include Merck KGaA, Thermo Fisher Scientific Inc., Brammer Bio, Spark Therapeutics, Fujifilm Holdings Corporation, Lonza, Kaneka Eurogentec, Finvector Vision Therapies, Cobra Biologics, Uniqure, Oxford Biomedica, Massbiologics, Novasep, Regenxbio, and Shape Therapeutics.

Key developments:

In January 2021: Thermo Fisher Scientific acquired Viral Vector's manufacturing business of Henogen SA, Novasep's in Belgium, for approximately EUR 725 million.

In January 2021: Fujifilm Corporation announced plans to invest USD 40 million, which will be used to establish a new processing facility for viral vector manufacturing and associated research.

In December 2020: Shape Therapeutics launched an innovative capsid discovery platform designed to improve the delivery and safety of gene therapies. The platform could generate adeno-associated virus (AAV) vectors that are tissue-specific.

In April 2020: Merck KgaA and its subsidiary MilliporeSigma announced plans to spend USD 110 million to open a second viral vector facility at its Carlsbad, California facility.

Diseases Covered:

Human Disease
Veterinary Disease

Types Covered:

Pox Virus
Cytomegalovirus
Herpes Simplex Virus Vectors
Adenoviral Vectors
Adeno-Associated Viral Vectors
Retroviral Vectors

Applications Covered:

Gene Therapy
Vaccinology

End Users Covered:

Biotech Companies
Pharmaceutical and Biopharmaceutical Companies
Research Institutes

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Viral Vector Manufacturing Market, By Disease

5.1 Introduction
5.2 Human Disease
- 5.2.1 Genetic Disorders
  - 5.2.1.1 Tuberculosis
  - 5.2.1.2 Human Immunodeficiency Virus (HIV)
- 5.2.2 Cancer
- 5.2.3 Infectious Diseases
  - 5.2.3.1 Malaria
  - 5.2.3.2 Influenza
  - 5.2.3.3 Hepatitis
5.3 Veterinary Disease
- 5.3.1 Infectious Bronchitis
- 5.3.2 Avian Influenza
- 5.3.3 Marek's Disease
- 5.3.4 Peste des Petits Ruminants (PPR) Disease
- 5.3.5 Other Veterinary Diseases
  - 5.3.5.1 Newcastle Disease
  - 5.3.5.2 Rabies
  - 5.3.5.3 Swine Influenza
  - 5.3.5.4 Equine Influenza
  - 5.3.5.5 Fibromuscular Dysplasia (FMD)

6 Global Viral Vector Manufacturing Market, By Type

6.1 Introduction
6.2 Pox Virus
6.3 Cytomegalovirus
6.4 Herpes Simplex Virus Vectors
6.5 Adenoviral Vectors
6.6 Adeno-Associated Viral Vectors
6.7 Retroviral Vectors
- 6.7.1 Lentiviral Vectors
- 6.7.2 Gamma-Retroviral Vectors

7 Global Viral Vector Manufacturing Market, By Application

7.1 Introduction
7.2 Gene Therapy
7.3 Vaccinology
- 7.3.1 Multivalent Vaccines
- 7.3.2 Multipathogen Vaccines

8 Global Viral Vector Manufacturing Market, By End User

8.1 Introduction
8.2 Biotech Companies
8.3 Pharmaceutical and Biopharmaceutical Companies
8.4 Research Institutes

9 Global Viral Vector Manufacturing Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Merck KGaA
11.2 Thermo Fisher Scientific Inc.
11.3 Brammer Bio
11.4 Spark Therapeutics
11.5 Fujifilm Holdings Corporation
11.6 Lonza
11.7 Kaneka Eurogentec
11.8 Finvector Vision Therapies
11.9 Cobra Biologics
11.10 Uniqure
11.11 Oxford Biomedica
11.12 Massbiologics
11.13 Novasep
11.14 Regenxbio
11.15 Shape Therapeutics

簡介目錄圖表

List of Tables

Table 1 Global Viral Vector Manufacturing Market Outlook, By Region (2020-2028) ($MN)
Table 2 Global Viral Vector Manufacturing Market Outlook, By Disease (2020-2028) ($MN)
Table 3 Global Viral Vector Manufacturing Market Outlook, By Human Disease (2020-2028) ($MN)
Table 4 Global Viral Vector Manufacturing Market Outlook, By Genetic Disorders (2020-2028) ($MN)
Table 5 Global Viral Vector Manufacturing Market Outlook, By Cancer (2020-2028) ($MN)
Table 6 Global Viral Vector Manufacturing Market Outlook, By Infectious Diseases (2020-2028) ($MN)
Table 7 Global Viral Vector Manufacturing Market Outlook, By Veterinary Disease (2020-2028) ($MN)
Table 8 Global Viral Vector Manufacturing Market Outlook, By Infectious Bronchitis (2020-2028) ($MN)
Table 9 Global Viral Vector Manufacturing Market Outlook, By Avian Influenza (2020-2028) ($MN)
Table 10 Global Viral Vector Manufacturing Market Outlook, By Marek's Disease (2020-2028) ($MN)
Table 11 Global Viral Vector Manufacturing Market Outlook, By Peste des Petits Ruminants (PPR) Disease (2020-2028) ($MN)
Table 12 Global Viral Vector Manufacturing Market Outlook, By Other Veterinary Diseases (2020-2028) ($MN)
Table 13 Global Viral Vector Manufacturing Market Outlook, By Type (2020-2028) ($MN)
Table 14 Global Viral Vector Manufacturing Market Outlook, By Pox Virus (2020-2028) ($MN)
Table 15 Global Viral Vector Manufacturing Market Outlook, By Cytomegalovirus (2020-2028) ($MN)
Table 16 Global Viral Vector Manufacturing Market Outlook, By Herpes Simplex Virus Vectors (2020-2028) ($MN)
Table 17 Global Viral Vector Manufacturing Market Outlook, By Adenoviral Vectors (2020-2028) ($MN)
Table 18 Global Viral Vector Manufacturing Market Outlook, By Adeno-Associated Viral Vectors (2020-2028) ($MN)
Table 19 Global Viral Vector Manufacturing Market Outlook, By Retroviral Vectors (2020-2028) ($MN)
Table 20 Global Viral Vector Manufacturing Market Outlook, By Lentiviral Vectors (2020-2028) ($MN)
Table 21 Global Viral Vector Manufacturing Market Outlook, By Gamma-Retroviral Vectors (2020-2028) ($MN)
Table 22 Global Viral Vector Manufacturing Market Outlook, By Application (2020-2028) ($MN)
Table 23 Global Viral Vector Manufacturing Market Outlook, By Gene Therapy (2020-2028) ($MN)
Table 24 Global Viral Vector Manufacturing Market Outlook, By Vaccinology (2020-2028) ($MN)
Table 25 Global Viral Vector Manufacturing Market Outlook, By Multivalent Vaccines (2020-2028) ($MN)
Table 26 Global Viral Vector Manufacturing Market Outlook, By Multipathogen Vaccines (2020-2028) ($MN)
Table 27 Global Viral Vector Manufacturing Market Outlook, By End User (2020-2028) ($MN)
Table 28 Global Viral Vector Manufacturing Market Outlook, By Biotech Companies (2020-2028) ($MN)
Table 29 Global Viral Vector Manufacturing Market Outlook, By Pharmaceutical and Biopharmaceutical Companies (2020-2028) ($MN)
Table 30 Global Viral Vector Manufacturing Market Outlook, By Research Institutes (2020-2028) ($MN)